CorMedix Reaffirms 2026 Total Revenue Guidance of $325 Million to $345 Million

• CorMedix reaffirmed full-year 2026 revenue guidance of $325 million to $345 million.
• CMS set DefenCath's Q1 2027 post-TDAPA add-on at $8.32 per dialysis session, versus $2.37 in the second half of 2026.
• The add-on is expected to decline in Q2 2027 before rising in Q3 and/or Q4, subject to CMS's treatment of utilization data.
• Each quarter's rate is expected to exceed $2.37, with the annual average more than double that level.
• Unaudited cash and cash equivalents totaled approximately $355 million as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.